Tiratricol is an triiodothyronine (T3) analogue used to treat peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency. Tiratricol is an analogue and active metabolite of the thyroid hormone triiodothyronine (T3).
- Mechanism
- Curator reviewed · 3 references
Monocarboxylate transporter 8 (MCT8) is involved in the transport of triiodothyronine (T3) and thyroxine (T4). Mutations in the SLC16A2 gene leading to MCT8 deficiency lead to impaired thyroid hormone uptake into the brain and elevated serum concentrations of T3. Tiratricol is biologically active, binds with high affinity to the thyroid hormone receptors TRα and TRβ and exerts similar biological effects to T3, although with different tissue specificity. Unlike T3 and T4, tiratricol enters MCT8 dependent cells without a functioning MCT8 transporter. Tiratricol can thereby replace T3 in MCT8 dependent tissues and restore normal thyroid hormone activity across tissues.
- Primary indication
- Tiratricol is indicated for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency (Allan-Herndon-Dudley Syndrome), from birth.Curator reviewed · 1 structured indication
- Formula / weight
- C14H9I3O4 · 621.9323 g/mol (avg)
- First approval
- European Union, 2025
- Also known as
- (4-(4-HYDROXY-3-IODOPHENOXY)-3,5-DIIODOPHENYL)ACETIC ACID · 3,5,3'-Triiodothyroacetate · BENZENEACETIC ACID, 4-(4-HYDROXY-3-IODOPHENOXY)-3,5-DIIODO- · TRIAC · Triiodothyroacetic acid
- Code names
- NSC-759294
Resolves to
UOWZUVNAGUAEQC-UHFFFAOYSA-NSMILESOC(=O)CC1=CC(I)=C(OC2=CC=C(O)C(I)=C2)C(I)=C1What you can answer from here — as of September 12, 2026
Which drugs share a target with Tiratricol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account